Benitec Biopharma Financials - Benzinga

Benitec Biopharma Inc

BNTCNASDAQ

Trade with Public

Trade with Public

$12.22

-0.23-1.85%

At close: Sep 10, 5:00 PM EST

$12.22

N/A

After Hours: 4:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Benitec Biopharma Financials

Benitec Biopharma (BNTC) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Benitec Biopharma Q3 EPS $(0.24) Beats $(0.27) Estimate

Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.27) by 11.11 percent. This is a 36.84 percent increase over losses of $(0.38) per share from

Benzinga Newsdesk

PRO
Benitec Biopharma Q2 EPS $(0.26) Misses $(0.22) Estimate

Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.22) by 16.59 percent. This is unchanged from the same period last year.

Benzinga Newsdesk

PRO
Benitec Biopharma Q1 EPS $(0.22) Beats $(0.41) Estimate

Benzinga Newsdesk

PRO
CORRECTION: Benitec Biopharma Q4 EPS $(0.42) Misses $(0.33) Estimate

Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.33) by 25.75 percent. This is a 30 percent increase over losses of $(0.60) per share from

Benzinga Newsdesk

PRO
Benitec Biopharma Q3 EPS $(0.24) Beats $(0.35) Estimate

Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.35) by 31.43 percent. This is a 85.37 percent increase over losses of $(1.64) per share from

Benzinga Newsdesk

PRO
Benitec Biopharma Q2 2025 GAAP EPS $(0.33) Beats $(0.87) Estimate

Benzinga Newsdesk